However, if we focus on advanced AMD, especially neovascular AMD, it is clear that ischemic change and hypoxic response play central roles, which is proven by the clinical efficacy of anti-VEGF antibody treatment [1]. This evidence concerns the gene VEGFA and age-related macular degeneration.